Cipla Rises On U.S. FDA Nod For Immunodeficiency Drug

Neal Bhai Reports (NBR) — Cipla Rises On U.S. FDA Nod For Immunodeficiency Drug – Shares of the Mumbai-based drugmaker rose as much as 6.47 percent to Rs 622.75 after U.S. FDA gave its final approval to Efavirenz tablets in strength of 600 mg. Efavirenz Tablets 600 mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s Sustiva which is used in treatment of human immunodeficiency virus type 1 infection, Cipla said in an exchange filing.

READ MORE…

Bond Yield Drops On Reserve Bank’s OMO Plan

Bond Yield Drops On Reserve Bank’s OMO Plan – Yield on India’s 10-year 7.17 percent bond expiring in January 2028 dropped 4 basis points to 7.82 percent after the Reserve Bank of India said it will buyback Rs 10,000 crore of debt via open market operations (OMO) on Thursday, the first …

READ MORE…

Stocks Check : Cipla, State Bank Of India And More

Stocks Check: Cipla, State Bank Of India And More 📌 State Bank of India won’t be able to merge more banks with self.        📌 UPL-led consortium is in exclusive talks to acquire Bill Ackman-backed Platform Specialty Products Corp.  📌 Cipla gets final approval for generic drug Sustiva.  📌 The wealth management …

READ MORE…

Pokarna Declines After Well Known Investor Sells Stake

Gold Silver Reports (GSR) – Pokarna Declines After Well Known Investor Sells Stake – Shares of the Secunderabad-based company engaged in business of granite quarrying fell as much as 3 percent to Rs 174.50 after well-known investor Ashish Kacholia sold 1.2 percent stake in the company.       

READ MORE…

Vedanta Set For Its Longest Losing Streak In Over Three Months

Gold Silver Reports (GSR) – Vedanta Set For Its Longest Losing Streak In Over Three Months – Shares of the metal maker extended its decline for the seventh straight session today, its longest losing streak since March 9. The stock fell as much as 3.3 percent to hit a 52-week low at Rs 230.65 apiece.

READ MORE…